YTHDF2 deficiency in TAMs suppress tumor growth and enhance cancer immunotherapy by reprogramming TAMs toward an antitumoral phenotype and increasing their antigen cross-presentation ability, which in turn enhanced CD8+T cell-mediated antitumor immunity. The gene discussed is CD8A; the disease is cancer.